Motilal Oswal has initiated coverage on Emcure Pharmaceuticals with a target price of INR 2,260. The brokerage forecasts a 21% revenue growth rate through FY26, supported by strong demand in European and Canadian markets. Investors may monitor whether the company maintains its current return on equity as it expands its international footprint.
Motilal Oswal has officially initiated research coverage on Emcure Pharmaceuticals, assigning the stock a buy recommendation and setting a target price of INR 2,260. This new outlook reflects the brokerage's expectations for the company's financial trajectory over the next few years.
Growth Drivers and Global Markets
The brokerage anticipates that Emcure will achieve a revenue compound annual growth rate (CAGR) of 21% between FY24 and FY26. Analysts project that revenues could reach INR 52 billion by FY26. A significant portion of this expected growth is attributed to the company's performance in international markets, particularly Europe and Canada. Specifically, the report notes that the company’s European business is expected to grow faster than many of its industry peers. In Canada, success is being driven by the company’s specialized marketing and distribution platforms, namely Marcan and Mantra.
Emcure has transitioned from a local manufacturer to an R&D-focused pharmaceutical business since its inception in 1981. This strategy has involved both internal growth and strategic acquisitions to build a presence in multiple countries. The company currently utilizes its Indian manufacturing base to supply these global markets.
Valuation and Financial Expectations
To arrive at the target price of INR 2,260, the brokerage applied a price-to-earnings (P/E) multiple of 28x. This valuation is based on the company's diversified income sources and an expected return on equity (RoE) of approximately 20% for the period between FY26 and FY28. The brokerage further projects that the company will continue to see a 16-18% growth rate across its international segments from FY26 through FY28.
Investor Context
While brokerage reports provide a forward-looking perspective, investors often track how such growth projections align with actual quarterly results. For a pharmaceutical company with significant international operations, currency fluctuations and changing regulatory requirements in overseas markets can impact profit margins. Additionally, the ability to successfully integrate previous investments and maintain efficient manufacturing operations remains a key monitorable. As Emcure continues to focus on its higher-value product portfolio, the consistency of its return ratios and its ability to manage debt levels will be important factors for shareholders to watch in upcoming financial updates.